<?xml version="1.0" encoding="UTF-8"?>
<p id="para0004">By contrast, the growing supply of biological therapies that lack scientific evidence or are offered outside the regulatory framework of various countries represents a recognized phenomenon [
 <xref rid="bib0011" ref-type="bibr">11</xref>,
 <xref rid="bib0012" ref-type="bibr">12</xref>]. The boom in businesses offering cell-based treatments, whether stem cell or otherwise, and platelet-enriched plasma (PRP) has been favored by the introduction to the market of devices that allow these biological products to be easily obtained from the patient's own tissues and blood and administered during the same procedure, as point-of-care therapies, often without all the required authorizations 
 <xref rid="bib0013" ref-type="bibr">[13]</xref>.
</p>
